Last reviewed · How we verify
PLASMINOGEN
At a glance
| Generic name | PLASMINOGEN |
|---|---|
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Abdominal pain
- Gastric dilatation (bloating/feel bloated)
- Nausea
- Fatigue
- Pain in extremity
- Hemorrhage
- Constipation
- Dry mouth
- Headache
- Dizziness
- Arthralgia
- Back pain
Serious adverse events
- Anti-plasminogen antibodies
Key clinical trials
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
- Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)
- Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |